Moberg Pharma AB (publ) (STO: MOB)
Sweden
· Delayed Price · Currency is SEK 18.66
-0.53 (-2.76%)
Nov 22, 2024, 3:56 PM CET
Moberg Pharma AB Company Description
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden.
It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013.
Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
Moberg Pharma AB (publ)
| Country | Sweden |
| Founded | 2006 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Anna Ljung |
Contact Details
Address: GustavslundsvAegen 42 Bromma, 167 51 Sweden | |
| Phone | 46 8 52 23 07 00 |
| Website | mobergpharma.se |
Stock Details
| Ticker Symbol | MOB |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0003613090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anna Ljung BA, M.Sc. | Chief Executive Officer |
| Marie Moberg | Co-Founder |
| Mark Beveridge | Vice President of Finance |
| Dr. Christina Erixon | Head of Pharmaceutical Development and Operations |
| Dr. Amir Tavakkol Ph.D. | Chief Scientific Officer |
| Gunilla Wengström | Senior Director of Sales and Marketing |
| Anders Broijersen M.D., Ph.D. | Chief Medical Officer |
| Robert Ehrl | Head of Supply |